AstraZeneca says antibody treatment failed in preventing COVID-19 in exposed patients
HEALTH & SCIENCEBy REUTERS | Tue,Jun 15 2021 12:29:43 EATBy REUTERS | Tue,Jun 15 2021 12:29:43 EAT
Anglo-Swedish drugmaker AstraZeneca (AZN.L) said on Tuesday a study of its monoclonal antibody treatment, AZD7442, did not meet the main goal of preventing symptomatic COVID-19 in people recently exposed to the novel coronavirus.
The company said the participants in the trial were unvaccinated adults older than 18 years with confirmed exposure to a person with the coronavirus within the past eight days.
AZD7442 reduced the risk of developing symptomatic COVID-19 by 33% compared to a placebo, which was not statistically significant, the company reported.
Covid 19 Time Series
"While this trial did not meet the primary endpoint against symptomatic illness, we are encouraged by the protection seen in the PCR negative participants following treatment with AZD7442," Mene Pangalos, AstraZeneca executive vice president, said in a statement.
AstraZeneca is also studying the treatment in a pre-exposed patients trial and for preventing more severe disease.
The monoclonal antibody therapy belongs to a class of drugs which mimic natural antibodies the body produces to fight off the infection.
Rivals Regeneron Pharmaceuticals Inc (REGN.O) and Eli Lilly & Co (LLY.N) have both developed monoclonal antibody therapies which have been authorised for use in the United States to treat patients infected with the virus. The European Medicines Agency (EMA) has approved Regeneron’s therapy and is reviewing similar drugs from Eli Lilly, Celltrion (068270.KS) and one developed by GlaxoSmithKline (GSK.L) and Vir Biotechnology Inc (VIR.O). read more
AstraZeneca in October enlisted Swiss contract manufacturer Lonza (LONN.S) to produce the antibody drug in Portsmouth, New Hampshire, starting in the first half of 2021.
AZD7442 is being developed with support from the U.S. government. AstraZeneca in March announced a deal with the U.S. government to supply up to half a million doses of AZD7442. The company said on Tuesday it is now in talks with the U.S. government regarding next steps on the deal.
Good laws set up to boost fishing, but policies are yet to take effect
Health & Science
By PROTUS ONYANGO
Mental illness is a chronic disease of the young
By DR. CHITAYI MURABULA AND MOITREYEE SINHA
Teen mums are between ‘Narok and a hard place’
By ROBERT KIPLAGAT
Eating at funerals increasing cases of Covid-19
Health & Science
By MURIITHI MUGO
Stressed? Have sweet potatoes, green tea
By AYOKI ONYANGO